besipirdine

structure given in first source; a non-receptor-dependent cholinomimetic agent with noradrenergic activity with potential use for treating Alzheimer's disease

Also Known As:

HP 749; HP-749; N-(n-propyl)-N-(4-pyridinyl)-1H-indol-1-amine hydrochloride; besipirdine hydrochloride; 1H-Indol-1-amine, N-propyl-N-4-pyridinyl-, monohydrochloride

Networked: 10 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - besipirdine: 10
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - besipirdine: 10

Experts

1.	Attali, Pierre: 1 article (01/2011)
2.	Bienaymé, Hugues: 1 article (01/2011)
3.	Ferté, Jacques: 1 article (01/2011)
4.	Lluel, Philippe: 1 article (01/2011)
5.	Ocaña, Ana V: 1 article (01/2011)
6.	Palea, Stefano: 1 article (01/2011)
7.	Pérez-Martínez, Francisco C: 1 article (01/2011)
8.	Rekik, Moèz: 1 article (01/2011)
9.	Vela-Navarrete, Remigio: 1 article (01/2011)
10.	Virseda, Julio: 1 article (01/2011)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/17/1996 - "The present study examined the efficacy and tolerability of two doses of besipirdine (5 and 20 mg BID) in 275 patients with Alzheimer's disease during 3 months of treatment and during 3 months after withdrawal of treatment. " 01/01/1996 - "The present study examined the efficacy and tolerability of two doses of besipirdine (5 and 20 mg b.i.d.) in 275 patients with Alzheimer disease during 3 months of treatment and for 3 months after withdrawal of treatment. " 01/01/1996 - "A treatment and withdrawal trial of besipirdine in Alzheimer disease." 01/01/1995 - "A "bridging" (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease." 01/19/1996 - "Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease."
2.	Polydipsia 01/01/1996 - "Besipirdine (HP 749) reduces schedule-induced polydipsia in rats."
3.	Urinary Incontinence 01/01/2011 - "These data support the potential of besipirdine as a new drug for LUT dysfunctions such as stress and mixed urinary incontinence."
4.	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/01/1996 - "The aim of the present paper is to report on the adrenergic and serotonergic effects of besipirdine (HP 749) in vivo and to discuss its potential use in the treatment of obsessive compulsive disorder. "
5.	Hypertension (High Blood Pressure) 04/01/1997 - "In conscious dogs, besipirdine (0.1-2 mg/kg, p.o.) also produced dose-related hypertension and bradycardia. "

Related Drugs and Biologics

1.	besipirdine
2.	Cholinergic Agents (Cholinergics)
3.	Adrenergic Agents (Adrenergic Drugs)
4.	N-(4-pyridinyl)-1H-indol-1-amine